A federal consultative group voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is not binding. The FDA has given no signal on whether it will adopt the suggestion. The move came after weeks of public comment sessions. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could redefine how the agency handles a part of the wellness market that is moving at speed. Market observers are watching to see if the FDA picks up the plan. A spokesperson offered no firm timeline for a response. Industry voices argue the change would widen access to substances some say help. Critics warn that looser rules could invite misuse across a barely regulated market. The advisory vote only sets up a possible shift, and the ultimate call rests with the federal agency.
Sources & References
-
FDA panel recommends loosening restrictions on controversial peptide - The Washington Post
FDA panel recommends loosening restrictions on controversial peptide The Washington Post
-
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition - Time Magazine
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition Time Magazine
-
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week - The American Journal of Managed Care
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week The American Journal of Managed Care
-
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers - AP News
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers AP News
-
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. - MarketWatch
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. MarketWatch